

Nostrum Pharmaceuticals signs new license agreement with IMTECH

On 23 February 2009, Nostrum Pharmaceuticals, USA, obtained a worldwide license to develop and commercialize Caerulomycin A, and its proprietary derivatives and analogues (“Caerulomycin”) for their novel indication of immuno-suppression. The license was obtained from Institute of Microbial Technology (IMTECH), Chandigarh.

Nostrum’s President and founder, Dr. Nirmal Mulye, expressed his appreciation for the continued efforts by IMTECH and Nostrum’s Symmetrix subsidiaries to pursue development of novel biopharmaceutical therapeutic protein drugs, including Caerulomycin and a clot busting protein known as Clot Specific Streptokinase obtained earlier pursuant to license from IMTECH.

Dr. Mulye and Dr. G. Sahni, Director, IMTECH, signed the licensing agreement at CSIR headquarters at a function that was attended by the Honorable Mr. Kapil Sibal, Minister of Science and Technology, Government of India, and Professor Samir K. Brahmachari, Director General, CSIR.